216 related articles for article (PubMed ID: 26984517)
1. Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association.
Shimada A; Kimura H; Oida K; Kanehara H; Bando Y; Sakamoto S; Wakasugi T; Saga T; Ito Y; Kamiyama K; Mikami D; Iwano M; Hirano T; Yoshida H
Lipids Health Dis; 2016 Mar; 15():57. PubMed ID: 26984517
[TBL] [Abstract][Full Text] [Related]
2. Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2012 Oct; 12(5):349-54. PubMed ID: 22900989
[TBL] [Abstract][Full Text] [Related]
3. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide suppresses liver X receptor β and enhances cholesteryl ester transfer protein expression without affecting the liver X receptor α in HepG2 cells.
Cheng TJ; Lin SW; Chen CW; Guo HR; Wang YJ
Chem Biol Interact; 2016 Oct; 258():288-96. PubMed ID: 27622732
[TBL] [Abstract][Full Text] [Related]
5. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
6. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
7. LXRalpha regulates human CETP expression in vitro and in transgenic mice.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Ubukata N; Terasaka N
Atherosclerosis; 2010 Sep; 212(1):139-45. PubMed ID: 20494359
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II.
Liu M; Chen Y; Zhang L; Wang Q; Ma X; Li X; Xiang R; Zhu Y; Qin S; Yu Y; Jiang XC; Duan Y; Han J
J Biol Chem; 2015 Jun; 290(23):14418-29. PubMed ID: 25914138
[TBL] [Abstract][Full Text] [Related]
9. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
Shimabukuro M; Higa M; Tanaka H; Shimabukuro T; Yamakawa K; Masuzaki H
Diabet Med; 2011 Jul; 28(7):856-64. PubMed ID: 21244474
[TBL] [Abstract][Full Text] [Related]
10. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Liu PY; Lin LY; Lin HJ; Hsia CH; Hung YR; Yeh HI; Wu TC; Chen JY; Chien KL; Chen JW
PLoS One; 2013; 8(10):e76298. PubMed ID: 24098467
[TBL] [Abstract][Full Text] [Related]
11. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
Saku K; Zhang B; Noda K;
Circ J; 2011; 75(6):1493-505. PubMed ID: 21498906
[TBL] [Abstract][Full Text] [Related]
12. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
13. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition.
Kettunen J; Holmes MV; Allara E; Anufrieva O; Ohukainen P; Oliver-Williams C; Wang Q; Tillin T; Hughes AD; Kähönen M; Lehtimäki T; Viikari J; Raitakari OT; Salomaa V; Järvelin MR; Perola M; Davey Smith G; Chaturvedi N; Danesh J; Di Angelantonio E; Butterworth AS; Ala-Korpela M
PLoS Biol; 2019 Dec; 17(12):e3000572. PubMed ID: 31860674
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
[TBL] [Abstract][Full Text] [Related]
17. Pitavastatin: an overview.
Saito Y
Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
[TBL] [Abstract][Full Text] [Related]
18. Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse.
Masson D; Staels B; Gautier T; Desrumaux C; Athias A; Le Guern N; Schneider M; Zak Z; Dumont L; Deckert V; Tall A; Jiang XC; Lagrost L
J Lipid Res; 2004 Mar; 45(3):543-50. PubMed ID: 14679166
[TBL] [Abstract][Full Text] [Related]
19. Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin.
Krikken JA; Waanders F; Dallinga-Thie GM; Dikkeschei LD; Vogt L; Navis GJ; Dullaart RP
Expert Opin Ther Targets; 2009 May; 13(5):497-504. PubMed ID: 19397474
[TBL] [Abstract][Full Text] [Related]
20. Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages.
Lakomy D; Rébé C; Sberna AL; Masson D; Gautier T; Chevriaux A; Raveneau M; Ogier N; Nguyen AT; Gambert P; Grober J; Bonnotte B; Solary E; Lagrost L
Arterioscler Thromb Vasc Biol; 2009 Nov; 29(11):1923-9. PubMed ID: 19679828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
